Sam Chun Dang Pharm Secures Exclusive U.S. Licensing Deal for Oral Obesity and Diabetes Treatment
Sam Chun Dang Pharm has entered into a significant license-out agreement with an undisclosed U.S. partner for the commercialization of oral...
Search results for "obesity diabetes treatment"
"It Wasn't Just Weight Loss That Improved My Knees"...Ozempic Study Confirms Cartilage 'Metabolic Changes'
"Please lose some weight." This is a common phrase heard when visiting a hospital for knee pain. As weight increases, the burden on the knee joints...
Does Mounjaro Harm Eye Health? Long-Term Study Shows Diabetic Retinopathy Risk Actually Drops
Concerns that Eli Lilly’s popular weight-loss and diabetes treatment, Mounjaro, might exacerbate eye complications in...
The Surprising Life-Saving Potential of Weight Loss Meds in Diabetic Foot Care
GLP-1 receptor agonists (such as Wegovy and Ozempic), currently dominating the headlines as weight loss medications,...
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour
Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s...
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide
JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
As the U.S. Reconsiders Direct-to-Consumer Drug Ads, What Lessons Should We Learn?
During a yearlong stay in the United States, one of the things that struck me most was how easy it is to come across...
Prevention vs. Treatment: Why Cancer Therapy Demands a Completely Different Diet
What makes diabetes particularly dangerous is the risk of severe, systemic complications.
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.